Apellis Pharmaceuticals’ (APLS) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research report sent to investors on Friday,Weiss Ratings reports.

Other research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. boosted their price objective on Apellis Pharmaceuticals from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Monday, August 4th. Robert W. Baird boosted their price objective on Apellis Pharmaceuticals from $47.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, July 18th. Royal Bank Of Canada boosted their price objective on Apellis Pharmaceuticals from $17.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Friday, August 1st. Morgan Stanley boosted their price objective on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 2nd. Finally, Citigroup boosted their price objective on Apellis Pharmaceuticals from $41.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Hold” and an average target price of $33.47.

Apellis Pharmaceuticals Stock Down 1.5%

Shares of NASDAQ:APLS opened at $28.17 on Friday. The stock has a market cap of $3.56 billion, a price-to-earnings ratio of -15.48 and a beta of 0.69. The company has a quick ratio of 3.16, a current ratio of 3.77 and a debt-to-equity ratio of 2.90. Apellis Pharmaceuticals has a 12-month low of $16.10 and a 12-month high of $35.72. The business’s 50 day moving average is $25.60 and its 200 day moving average is $21.46.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Thursday, July 31st. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.11. The company had revenue of $171.39 million for the quarter, compared to analysts’ expectations of $187.91 million. Apellis Pharmaceuticals had a negative return on equity of 116.09% and a negative net margin of 30.24%.Apellis Pharmaceuticals’s quarterly revenue was down 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. On average, sell-side analysts forecast that Apellis Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Transactions at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,000 shares of the stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $25.22, for a total transaction of $126,100.00. Following the sale, the general counsel owned 113,730 shares of the company’s stock, valued at approximately $2,868,270.60. This represents a 4.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Cedric Francois sold 175,037 shares of the stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $28.19, for a total value of $4,934,293.03. Following the sale, the chief executive officer directly owned 357,909 shares in the company, valued at $10,089,454.71. This trade represents a 32.84% decrease in their position. The disclosure for this sale can be found here. Insiders sold 312,921 shares of company stock worth $8,490,866 over the last quarter. 6.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Apellis Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Woodline Partners LP lifted its holdings in Apellis Pharmaceuticals by 15.5% during the 1st quarter. Woodline Partners LP now owns 218,850 shares of the company’s stock worth $4,786,000 after purchasing an additional 29,373 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Apellis Pharmaceuticals by 43.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 100,666 shares of the company’s stock worth $1,838,000 after purchasing an additional 30,507 shares in the last quarter. Cerity Partners LLC lifted its holdings in Apellis Pharmaceuticals by 16.7% during the 1st quarter. Cerity Partners LLC now owns 54,444 shares of the company’s stock worth $1,191,000 after purchasing an additional 7,777 shares in the last quarter. Bayforest Capital Ltd increased its stake in Apellis Pharmaceuticals by 431.9% in the 1st quarter. Bayforest Capital Ltd now owns 52,338 shares of the company’s stock worth $1,145,000 after acquiring an additional 42,499 shares during the last quarter. Finally, Pallas Capital Advisors LLC increased its stake in Apellis Pharmaceuticals by 29.0% in the 2nd quarter. Pallas Capital Advisors LLC now owns 54,849 shares of the company’s stock worth $949,000 after acquiring an additional 12,315 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).